Drug Profile
Research programme: mutilin-quinolone hybrid antibacterials - Kyorin
Alternative Names: AM-3005; Compound 25 (AM-3005) - Kyorin; Mutilin-quinolone hybrids - KyorinLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Kyorin Pharmaceutical
- Class Fluoroquinolones; Ketones; Polycyclic compounds
- Mechanism of Action Protein synthesis inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Gram-positive-infections in Japan (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Methicillin-resistant-Staphylococcus-aureus-infections in Japan (Parenteral)
- 10 Nov 2008 Preclinical trials in Gram-positive infections in Japan (Parenteral)